This thesis explores the advancement of novel drugs for the treatment of hepatitis, particularly hepatitis B virus (HBV) and hepatitis C virus (HCV) infections, and aims to investigate and present the recent advancements in drug development, highlighting innovative approaches and potential drug candidates. The primary focus is directed on the progress made in developing direct-acting antivirals (DAAs) for HBV and HCV. The thesis discusses different classes of DAAs, such as protease inhibitors, polymerase inhibitors, and viral entry and assembly inhibitors. Moreover, the thesis emphasizes the exploration of future drug targets within the viral life cycle and the intricate interactions between the virus and its host. The findings presented in this thesis underscore the significance of ongoing research and clinical trials in hepatitis drug development. By expanding the range of treatment options, improving patient care, and addressing challenges such as drug resistance, novel drugs have the potential to significantly impact the management and control of HBV and HCV infections.